HR 5629 110th Congress House Health Administrative fees Administrative procedure Administrative remedies Child health Civil actions and liability Clinical trials Confidential communications Department of Health and Human Services Drug approvals Drugs Economics and Public Finance Environmental Protection Families Food and Drug Administration (FDA) Government Operations and Politics Government publicity Intellectual property Law Licenses

Pathway for Biosimilars Act

Introduced: March 13, 2008 See on congress.gov

Everywhere this bill has been 5 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Apr 14, 2008

Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

Mar 13, 2008

Referred to the Subcommittee on Health.

Mar 13, 2008

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Mar 13, 2008

Sponsor introductory remarks on measure. (CR E401-402)

Mar 13, 2008

Introduced in House

Plain-English summary Congressional Research Service

Pathway for Biosimilars Act - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product).

Requires the Secretary of Health and Human Services to approve the application if: (1) the biological product is biosimilar to the reference product with respect to each condition of use for which the reference product is approved; and (2) the applicant consents to the inspection of the facility that is the subject of the application.

Sets forth requirements for a determination by the Secretary that a biological product is interchangeable with a reference product.

Prohibits a biological product from being evaluated against more than one reference product.

Prohibits licensure under this Act of a biological product containing specified agents or toxins.

Prohibits the Secretary from making approval of an application under this Act effective until 12 yeas after the date on which the reference product was first licensed.

Provides for confidentiality of information received pursuant to this Act.

Sets forth provisions governing patent infringement actions related to this Act.

Deems as patent infringement the submission of a statement under this Act by the applicant setting forth reasons why the making, use, or sale of the biosimilar product would not infringe the patent, or why the patent is invalid or unenforceable, if the purpose of such submission is to obtain approval to engage in the commercial manufacture, use, or sale before the expiration of such patent.

What's happening now April 14, 2008

Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

Committees of jurisdiction 4